ABSTRACT
INTRODUCTION
Pre-eclampsia (PE) complicates 2-3% of pregnancies and the risk for PE increases with advancing maternal age, increasing weight, Afro-Caribbean and South Asian racial origin, previous pregnancy with PE, conception by in-vitro fertilization and medical history of chronic hypertension (CH), diabetes mellitus and systemic lupus erythematosus (SLE) or antiphospholipid syndrome (APS) 1 . The greatest risk factor for PE is medical history of CH, which is found in 1-2% of pregnancies; the risk of both preterm and term PE, after adjustment for maternal demographic characteristics, medical history and obstetric history, is 5-6 times higher in women with CH than in those without CH 2 . In PE, particularly preterm PE, there is impairment in the physiological process of trophoblastic invasion of the maternal spiral arteries and their remodeling from tortuous narrow muscular vessels into large non-muscular channels [3] [4] [5] . Reduced perfusion of the placenta causes oxidative stress that triggers release of trophoblast-derived factors which enter the maternal circulation and cause generalized endothelial dysfunction and an exaggerated inflammatory response that underlies many of the changes observed in PE [6] [7] [8] [9] [10] [11] . In some women with medical disorders, such as CH, there is endothelial dysfunction even before pregnancy and it was proposed that, in such cases, PE can develop in the absence of impaired placentation; the pre-existing endothelial dysfunction is exacerbated by the physiological burden of pregnancy, as normal pregnancies carry a low-grade systemic inflammatory response [12] [13] [14] [15] .
The aim of this study in pregnancies that develop PE was to examine possible differences between women with and those without CH in measures of impaired placental perfusion, assessed by uterine artery Doppler, and placental function, reflected in decreased maternal serum levels of placental growth factor (PlGF) and pregnancy-associated plasma protein-A (PAPP-A) at 11-13 weeks' gestation.
METHODS
The data for this study were derived from prospective screening for adverse outcomes in women with singleton pregnancy attending their first routine hospital visit at King's College Hospital, London, UK (between March 2006 and July 2015) and Medway Maritime Hospital, Kent, UK (between February 2007 and November 2015). This visit, which was held at 11 + 0 to 13 + 6 weeks of gestation, included recording of maternal characteristics and medical history 1 and measurements of uterine artery pulsatility index (UtA-PI) by transabdominal color Doppler ultrasound 16 , mean arterial pressure (MAP) by validated automated devices and standardized protocol 17 , and serum concentration of PlGF and PAPP-A (DELFIA Xpress system, PerkinElmer Life and Analytical Sciences, Waltham, USA). Gestational age was determined from measurement of fetal crown-rump length 18 . Written informed consent was obtained from women who agreed to participate in the study, which was approved by the ethics committee of each participating hospital. Data on pregnancy outcomes were collected from the hospital maternity records and the women's general medical practitioners.
The inclusion criteria for this study were pregnancies that developed PE and delivered phenotypically normal babies that were liveborn or stillborn at ≥ 24 weeks' gestation. The diagnosis of PE was made according to the guidelines of the International Society for the Study of Hypertension in Pregnancy 19 . PE was defined as systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg on at least two occasions 4 h apart developing after 20 weeks' gestation in a previously normotensive woman. In addition, there should be significant proteinuria (≥ 300 mg in 24 h or two readings of at least ++ on dipstick analysis of midstream or catheter urine specimen if no 24-h collection was available). In CH, diagnosis of superimposed PE requires development of significant proteinuria after 20 weeks' gestation in a previously non-proteinuric woman.
Statistical analysis
Comparison of maternal characteristics and obstetric history between pregnancies with and without CH was by the χ 2 -square test or Fisher's exact test for categorical variables and the Mann-Whitney U-test for continuous variables.
The measured MAP, UtA-PI, PlGF and PAPP-A were converted to multiples of the median (MoM) after Data are given as median (interquartile range) or n (%). *P < 0.0001 compared to women without CH. APS, antiphospholipid syndrome; DM, diabetes mellitus; GA, gestational age at recruitment; SLE, systemic lupus erythematosus.
adjustment for maternal characteristics and medical history [20] [21] [22] [23] . Regression analysis was used to determine the association between MoM values of each biomarker and gestational age at delivery with PE, and the slope and intercepts of the regression lines were compared for pregnancies with and without CH. Comparison of slopes of the regression lines between the two groups was carried out with Potthoff analysis, by introducing interaction terms in the linear regression analysis 24 . If there was no significant difference between slopes in the two groups, then the intercepts of the regression lines were compared by examining the coefficient (95% CI) for CH 25 . The statistical software package SPSS Statistics version 20.0 (SPSS Inc., Chicago, IL, USA) and MedCalc Statistical Software version 17.2 (MedCalc Software bvba, Ostend, Belgium) were used for data analyses.
RESULTS
During the study period, first-trimester screening was carried out in 283 pregnancies with CH that developed PE and 2236 pregnancies without CH that developed PE. Delivery < 37 weeks' gestation occurred in 36.0% (102/283) of the CH group and in 27.5% (615/2236) in those without CH. The maternal characteristics and medical and obstetric histories of the two groups are compared in Table 1 . In pregnancies with CH, compared to those without CH, median maternal age and weight were higher, and there were higher proportions of women of Afro-Caribbean racial origin, with medical history of SLE/APS and Type II diabetes mellitus, and parous women with previous pregnancy with or without PE. In both groups with and without CH, measurements of MAP and UtA-PI were increased, whereas those of PlGF and PAPP-A were decreased and the deviation from normal in all biomarkers decreased with advancing gestational age at delivery with PE ( Figure 1 ).
There was no significant difference between women with and without CH in the slope of the regression line of log 10 MoM biomarker values against gestational age at delivery with PE for MAP (P = 0.282), UtA-PI (P = 0.138), PlGF (P = 0.115) or PAPP-A (P = 0.435) ( Table 2 ). However, there was a significant difference in the intercept and coefficients of biomarkers in the two groups; compared to those without CH, MAP MoM, PlGF MoM and PAPP-A MoM were higher and UtA-PI MoM was lower in the CH group (all P < 0.01) (Figure 1 ).
DISCUSSION

Principal findings of the study
The findings of this study demonstrate that, in pregnancies that develop PE, in both women with CH and those without CH, at 11-13 weeks' gestation, first, MAP and UtA-PI are increased and PlGF and PAPP-A are decreased, and second, the deviation from normal in these biomarkers decreases with advancing gestational age at delivery with PE and the differences are therefore greater in early than late PE. The slope of the relationship between biomarker levels and gestational age at delivery is similar in those with CH and those without CH. However, for the same severity of PE, reflected in the gestational age at delivery, in the CH group, the deviation in UtA-PI, PlGF and PAPP-A is lower. In pregnancies with CH, MAP at 11-13 weeks' gestation is inevitably considerably higher in those with CH than in those without CH.
The findings of the study provide support for the hypothesis that, in medical conditions with coexisting endothelial dysfunction, such as CH, the degree of placental impairment necessary to trigger development of PE may be lower than in pregnancies without such pre-existing endothelial dysfunction 12, 13 .
Strengths and limitations
The strengths of this study are, first, examination of a large population of pregnancies with and without CH that developed PE, second, use of a specific methodology and appropriately trained doctors to measure UtA-PI and MAP, third, use of automated machines to provide accurate measurement of maternal serum concentration of metabolites that have been shown to be altered in pregnancies associated with impaired placentation, fourth, expression of the values of the biomarkers as MoMs after adjustment for factors that affect the measurements, and fifth, comparison of levels of biomarkers in women with and without CH, by taking into account the gestational age at delivery with PE. A limitation of the study is that we did not include measurement of potential biomarkers of inflammation and endothelial dysfunction. In previous studies, we reported that, at 11-13 weeks' gestation in pregnancies that develop PE, there are increased maternal circulating levels of the inflammatory factors pentraxin 3, matrix metalloproteinase-9 and the soluble receptor-1 of the tumor necrosis factor-α, as well as P-selectin, a marker of platelet activation [26] [27] [28] [29] . We found that the altered levels in these biomarkers were not associated with the degree of impairment in placental perfusion reflected in UtA-PI. However, we did not investigate whether there are differences in the levels of these biomarkers between pregnancies with CH and those without CH.
Comparison with previous studies
Several studies have documented that development of PE is associated with a first-trimester increase in UtA-PI and MAP and a decrease in serum PlGF and PAPP-A 16, [30] [31] [32] [33] [34] [35] . In this study, we compared biomarker levels in women with and those without CH. Previous studies have documented the association between CH and endothelial dysfunction and inflamation 36, 37 . However, we could not identify reports comparing first-trimester biomarkers in PE in women with and without CH.
Clinical implications of the study
The incidence of CH is 1-2% and, in these women, the risk of PE is > 20%; in this respect, a history of CH is the strongest risk factor for PE, compared to other factors in maternal demographic characteristics and medical history 1, 2 . Effective first-trimester screening for PE is provided by a combination of maternal factors and MAP, UtA-PI, PlGF and PAPP-A 34, 35 . In pregnancies with CH that develop PE, the smaller deviation from normal in UtA-PI, PlGF and PAPP-A is compensated for by the considerably higher levels of MAP. The rationale for first-trimester prediction of PE by a combination of maternal factors and biomarkers 33, 34 is that pharmacological intervention with low-dose aspirin in the high-risk group could potentially reduce the incidence of the disease 38, 39 . It is uncertain whether the potential benefit of low-dose aspirin is mediated through an effect on improving placentation or through its anti-inflammatory properties, and the extent to which this medication will be equally effective in prevention of PE in pregnancies with and without CH remains to be determined.
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